Bernard Prigent, MD, MBA
Under his leadership, Pfizer Canada has become one of the top R&D investors within the Canadian Life Science Sector. These investments cover most aspects of pharmaceutical R&D from discovery to clinical trials as well as alliances with the biotech sector and partnerships with academic institutions, federal and provincial funding agencies.
His current activities within the Life Science Sector include:
- Chair of the Scientific Committee of the Research Foundation of Rx&D
- Member of the Strategic Advisory Committee of the Center of Excellence in Personalized Medicine (CEPMed)
- Board Member of the Center of Excellence in the Prevention of Organ Failure (PROOF)
- Chairman of the Strategic Orientation Committee of Quebec Consortium for Drug Discovery (CQDM)
- Board Member of the Alberta Institute of Health Economics
- Board Member of the Canadian Dementia Knowledge Translation Network (CDKTN)
- Co-President of The Research Working Group of Montreal In Vivo
Dr. Prigent joined Pfizer in 1995 and occupied positions of increasing responsibility before becoming Vice-President and Medical director in January 2001.
Bernard Prigent started his career as a family physician in France, he subsequently completed his MD in the field of Tropical medicine and Public Health and for five years worked in various challenging clinical and hospital settings in France, Asia and Australasia.
He joined the pharmaceutical industry in 1984, working for the international medical and clinical research operations of three major European based pharmaceutical companies before coming to Pfizer Canada in 1995. His broad experience in pharmaceutical medicine was acquired working on the clinical development and commercialization of numerous new medicines in a variety of therapeutic areas.
His interest in the management of R&D organizations led him to complete his MBA at Henley Management College in 1992.
